Mélanie Bourassa Forcier, Vice-Chairperson and Acting Chairperson of the Patented Medicine Prices Review Board (PMPRB), confirmed her resignation from the Board on Twitter on December 7, 2022. In her comment she indicated she is evaluating her legal obligations concerning whether she can share the reasons for her resignation. PMPRB has not yet commented on the resignation or its potential implications for implementation of Final Guidelines. Final guidelines were expected to become effective on January 1, 2023, following a Consultation on PMPRB’s Proposed Guidelines which closed yesterday.

Stay tuned to PDCI’s TargetPharma Newsletter for more information analysis of the implications going forward.